Healthcare | July 05, 2022
Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries
Medicines, including insulin, to be available in 40 lower-income countries
Medicines, including insulin, to be available in 40 lower-income countries
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Pharmapack Europe recognizes excellence and innovation from exhibitors across connected devices, sustainability, supply chain logistics, route of administration, and packaging innovation, as well from the wider industry for patient-centric design and eco-design
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
Subscribe To Our Newsletter & Stay Updated
